Cargando…

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience

The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immune checkpoint inhibitors that disrupt the T-cell inhibitory interaction between the programmed cell death (PD)-1 receptor and its ligand (PD-L1). Pembrolizumab, a highly specific, monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crist, Michael, Iyer, Gopa, Hsu, Miles, Huang, William C., Balar, Arjun V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452591/ https://www.ncbi.nlm.nih.gov/pubmed/31057668 http://dx.doi.org/10.1177/1756287219839285

Ejemplares similares

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
por: Andreatos, Nikolaos, et al.
Publicado: (2020)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
por: Fukiishi, Yousuke, et al.
Publicado: (2022)

A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA
por: Sakai, Daiki, et al.
Publicado: (2023)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
por: Grivas, Petros, et al.
Publicado: (2020)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
por: Liu, Yung-Hao, et al.
Publicado: (2021)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
por: Bambury, Richard M, et al.
Publicado: (2015)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2022)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
por: Katims, Andrew B., et al.
Publicado: (2022)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
por: Fischer, Christine, et al.
Publicado: (2020)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma
por: Tomioka-Inagawa, Risa, et al.
Publicado: (2022)

Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
por: Xu, Zhenying, et al.
Publicado: (2022)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma
por: Huang, Yun-Ching, et al.
Publicado: (2016)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
por: Teshima, Taro, et al.
Publicado: (2022)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis
por: Yanagisawa, Takafumi, et al.
Publicado: (2021)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort
por: Ito, Katsuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jvcik9dukpm275nl7av4qb2tnm